Skip to content

PRP Intrauterine Infusion in Thawed Embryo Cycles

Intrauterine Infusion of Platelet-rich Plasma Infusion Before Thawed Embryo Transfer in Repeated Implantation Failure: A Randomized Controlled Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03734042
Enrollment
102
Registered
2018-11-07
Start date
2018-12-01
Completion date
2021-10-31
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluations

Keywords

Platelet rich plasma, Intrauterine infusion, Thawed embryos, IVF/ICSI cycles

Brief summary

All patients prepared to thawed embryo transfer were classified into 2 groups one group will receive platelet rich plasma (PRP) infusion intrauterine and the other group will not receive platelet rich plasma (PRP) infusion

Detailed description

Patients candidates for Thawed embryo transfer with Repeated implantation failure were recruited from 3 centers and classified into 2 groups: Group I: Will receive platelet rich plasma (PRP) intrauterine infusion at day 11 Group II: Not receiving platelet rich plasma (PRP)

Interventions

platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11

BIOLOGICALNormal saline

Intrauterine infusion of normal saline at day 11

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

2 groups parallel

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Patients age 20-35 years * Patients with previous implantation failure * Patients with thin endometrium\<7 mm

Exclusion criteria

* Patients older than 40 years * Patients with fresh embryo transfer * Patients with abnormal uterine cavity septate, or bicornuate uterus * Patients with abnormal male factor or tubal factor * Patients with abnormal embryos grade B or C. * Patients with immunological disorders as thyroidits or systemic lupus or rheumatoid arthritis

Design outcomes

Primary

MeasureTime frameDescription
Endometrial thickness8 daysThe increase in endometrial thickness at day of ET
Pregnancy rate15 daysNumber of cases who got pregnant

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026